OSE Immunotherapeutics Unveils a First-in-Class Antibody Against Chronic Inflammation
OSE Immunotherapeutics announces the presentation of a new FPR2 agonist monoclonal antibody, described as first-in-class, at the 2026 American Association of Immunologists (AAI) Congress held in Boston from April 15 to 19, 2026. This molecule is part of a therapeutic strategy based on the biology of inflammation resolution.
Innovative Approach to Inflammation Resolution
The FPR2 agonist monoclonal antibody developed by OSE Immunotherapeutics targets FPR2, a G protein-coupled receptor (GPCR) involved in initiating the resolution of inflammation. According to the company, this approach aims to activate the body's natural inflammation resolution mechanisms for the treatment of chronic inflammatory diseases. The molecule introduces a new strategy by actively triggering inflammation resolution, limiting neutrophil recruitment, and reprogramming macrophages towards a pro-resolutive anti-inflammatory state. Aurore Morello, Chief Scientific Officer at OSE Immunotherapeutics, will present this strategy for the first time at the AAI Congress.
Positioning in the Emerging Field of Resolution Biology
OSE Immunotherapeutics positions this FPR2-targeting strategy within the rapidly emerging field of resolution biology. The company justifies this approach by highlighting the significant unmet medical needs in the treatment of chronic inflammatory diseases, where current treatments primarily rely on long-term suppression of immune cells rather than restoring physiological balance. The preclinical efficacy of the antibody in several inflammatory disease models, according to the company, opens new opportunities for treating both acute and chronic inflammatory conditions.
